We are live on
!
Find out more
SCM
Silverarc Capital Management Portfolio holdings
AUM
$980M
1-Year Est. Return
470.8%
This Fund
S&P 500
This Quarter
Est. Return
+44.51%
1 Year Est. Return
+470.8%
3 Year Est. Return
+3,352.06%
5 Year Est. Return
+7,957.7%
10 Year Est. Return
–
AUM
$350M
AUM Growth
+$53.9M
(+18%)
Cap. Flow
+$2.7M
Cap. Flow
% of AUM
0.77%
Top 10 Holdings %
Top 10 Hldgs %
33.5%
Holding
108
New
29
Increased
39
Reduced
21
Closed
18
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CINC
CinCor Pharma, Inc. Common Stock
CINC
|
+$9.42M |
| 2 |
NUVL
Nuvalent
NUVL
|
+$7.29M |
| 3 |
Biogen
BIIB
|
+$6.21M |
| 4 |
Madrigal Pharmaceuticals
MDGL
|
+$4.88M |
| 5 |
TERN
Terns Pharmaceuticals
TERN
|
+$4.56M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Veracyte
VCYT
|
+$10.8M |
| 2 |
APEN
Apollo Endosurgery, Inc.
APEN
|
+$6.26M |
| 3 |
AKRO
Akero Therapeutics
AKRO
|
+$5.48M |
| 4 |
Cogent Biosciences
COGT
|
+$5.3M |
| 5 |
Nkarta
NKTX
|
+$4.77M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 79.93% |
| 2 | Technology | 0.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Codexis
CDXS
$151M
| $674K | 0.19% |
144,737
-700
| -0.5% | -$3.84K |
|
77
Design Therapeutics
DSGN
$761M
| $585K | 0.17% |
+57,025
| New | +$773K |
|
78
Immunic
IMUX
$190M
| $491K | 0.14% |
+35,066
| New | +$956K |
|
79
Compugen
CGEN
$222M
| $478K | 0.14% |
+667,443
| New | +$582K |
|
80
MeiraGTx Holdings
MGTX
$1.09B
| $370K | 0.11% |
56,672
+1,330
| +2% | +$9.13K |
|
81
Wave Life Sciences
WVE
$1.09B
| $350K | 0.1% |
+50,000
| New | +$230K |
|
82
Braze
BRZE
$2.81B
| $273K | 0.08% |
+10,000
| New | +$279K |
|
83
Praxis Precision Medicines
PRAX
$8.58B
| $234K | 0.07% |
6,561
-106
| -2% | -$3.31K |
|
84
uniQure
QURE
$3.03B
| $227K | 0.06% |
+10,000
| New | +$216K |
|
85
Gossamer Bio
GOSS
$82.9M
| $217K | 0.06% |
+100,000
| New | +$823K |
|
86
Evogene
EVGN
$5.7M
| $105K | 0.03% |
15,036
-1,715
| -10% | -$12.1K |
|
87
Viridian Therapeutics
VRDN
$2.09B
| $87.6K | 0.03% |
+3,000
| New | +$69.1K |
|
|
ELOX
88
DELISTED
Eloxx Pharmaceuticals, Inc. Common Stock
ELOX
| $48.9K | 0.01% |
26,876
-586
| -2% | -$2.83K |
|
|
FRTX
89
DELISTED
Fresh Tracks Therapeutics, Inc. Common Stock
FRTX
| $15K | ﹤0.01% |
+10,000
| New | +$17.7K |
|
|
MSACW
90
DELISTED
Medicus Sciences Acquisition Corp. Warrant
MSACW
| $4.5K | ﹤0.01% |
49,990
| – | – |
|
91
Arvinas
ARVN
$518M
| – | – |
-40,741
| Closed | -$1.81M |
|
92
PUT
Clene
CLNN
$64M
| – | – |
-86,740
| Closed | -$4.86M |
|
|
ESPR
93
DELISTED
Esperion Therapeutics
ESPR
| – | – |
-314,095
| Closed | -$2.1M |
|
|
ETNB
94
DELISTED
89bio
ETNB
| – | – |
-250,000
| Closed | -$1.45M |
|
95
EyePoint Inc
EYPT
$1.03B
| – | – |
-108,285
| Closed | -$857K |
|
|
NCNA
96
NuCana
NCNA
$5.49M
| – | – |
-54
| Closed | -$282K |
|
|
97
Nkarta
NKTX
$150M
| – | – |
-362,377
| Closed | -$4.77M |
|
98
PUT
Prothena Corp
PRTA
$425M
| – | – |
-5,000
| Closed | -$303K |
|
99
PUT
PolyPid
PYPD
$82.3M
| – | – |
-1,667
| Closed | -$59K |
|
100
Regenxbio
RGNX
$620M
| – | – |
-110,085
| Closed | -$2.91M |
|
Similar funds
BIP
MVM
MFWP
FCM
KL
GFP
ADIC
PCM
Silverarc Capital Management's Q4 2022 Portfolio in Review
As of Q4 2022, Silverarc Capital Management held 108 positions worth $350M, up 18% from $296M the previous quarter. Its ten largest holdings account for 33% of the portfolio.
Silverarc Capital Management's Q4 2022 filing shows 29 new, 39 increased, 21 reduced and 18 closed positions. Its largest new stake was CinCor Pharma, Inc. Common Stock: 395,382 shares worth $4.86M. The largest sale was Veracyte, an estimated $10.8M.
By sector, the portfolio is most concentrated in Healthcare at 80% of assets, up from 77% a quarter earlier, followed by Technology.
- Silverarc Capital Management's largest Q4 2022 buy was CinCor Pharma, Inc. Common Stock: 395,382 shares worth $4.86M.
- Silverarc Capital Management added most to Nuvalent in Q4 2022, an estimated $7.29M increase.
- Silverarc Capital Management's biggest Q4 2022 reduction was Veracyte, cutting an estimated $10.8M.
- Silverarc Capital Management fully exited Apollo Endosurgery, Inc. in Q4 2022, selling an estimated $6.26M.
- Silverarc Capital Management's ten largest holdings make up 33% of its $350M portfolio in Q4 2022.
- Silverarc Capital Management opened 29 new positions and closed 18 in Q4 2022.
- Silverarc Capital Management's portfolio value rose 18% quarter-over-quarter to $350M.
Based on Silverarc Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.